{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"4"}],"units":"Participants"}],"description":"Blood assay: Plasma inhibitory assay (PIA) measuring pFLT3 in blood at 24 hours post-dose","groups":[{"description":"Cohort 1: Participants were administered E6201 240 mg/m\\^2 IV over 2 hours once weekly, on Days 1, 8, 15, and 22, repeated every 28 days (= 1 cycle) until progression of disease, toxicity or other reason for discontinuation of study drug, and followed for up to 6 months after the last dose.","id":"OG000","title":"E6201 240 mg/m^2 Weekly"},{"description":"Cohort 2: Participants were administered E6201 320 mg/m\\^2 IV over 2 hours once weekly, on Days 1, 8, 15, and 22, repeated every 28 days (= 1 cycle) until progression of disease, toxicity or other reason for discontinuation of study drug, and followed for up to 6 months after the last dose.","id":"OG001","title":"E6201 320 mg/m^2 Weekly"},{"description":"Cohort 3: Participants were administered E6201 160 mg/m\\^2 IV over 2 hours twice weekly, on Days 1, 4, 8, 11, 15, 18, 22 and 25, repeated every 28 days (= 1 cycle) until progression of disease, toxicity or other reason for discontinuation of study drug, and followed for up to 6 months after the last dose.","id":"OG002","title":"E6201 160 mg/m^2 Twice Weekly"},{"description":"Cohort 4: Participants were administered E6201 240 mg/m\\^2 IV over 2 hours twice weekly, on Days 1, 4, 8, 11, 15, 18, 22 and 25, repeated every 28 days (= 1 cycle) until progression of disease, toxicity or other reason for discontinuation of study drug, and followed for up to 6 months after the last dose.","id":"OG003","title":"E6201 240 mg/m^2 Twice Weekly"},{"description":"Cohort 5: Participants were administered E6201 320 mg/m\\^2 IV over 2 hours twice weekly, on Days 1, 4, 8, 11, 15, 18, 22 and 25, repeated every 28 days (= 1 cycle) until progression of disease, toxicity or other reason for discontinuation of study drug, and followed for up to 6 months after the last dose.","id":"OG004","title":"E6201 320 mg/m^2 Twice Weekly"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All subjects in the FAS who completed at least 1 PD assessment. Data obtained were not quantitative.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1, 24 hours post-dose.","title":"Number of Participants With Suppression of pFLT3 by PIA at 24 Hours Post-dose","type":"SECONDARY","unitOfMeasure":"Participants"}